Prothena (PRTA) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRTA shares.
View PRTA analyst ratings or view top-rated stocks.

9 brokerages have issued 1 year target prices for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $129.00. On average, they predict the company's stock price to reach $90.38 in the next year. This suggests a possible upside of 86.5% from the stock's current price.
View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts.

Prothena's stock was trading at $60.25 at the beginning of the year. Since then, PRTA stock has decreased by 19.6% and is now trading at $48.45.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PRTA earnings forecast.

Prothena Co. plc (NASDAQ:PRTA) issued its earnings results on Thursday, August, 3rd. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.11. The biotechnology company earned $4.02 million during the quarter, compared to analyst estimates of $5.09 million. Prothena had a negative trailing twelve-month return on equity of 25.43% and a negative net margin of 244.45%. The business's revenue for the quarter was up 206.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.88) EPS.

ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3X Shares (LABU) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Prothena's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.75%), State Street Corp (3.50%), Dimensional Fund Advisors LP (2.15%), Geode Capital Management LLC (1.57%), Bank of New York Mellon Corp (0.97%) and Nuveen Asset Management LLC (0.85%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends.

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRTA stock can currently be purchased for approximately $48.45.

Prothena (NASDAQ:PRTA) has a market capitalization of $2.59 billion and generates $53.90 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.

The company employs 127 workers across the globe.

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.